This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M07.1 | Special Copayment Reduction: V237 (severe intractable disease, 5 years) |
| B. Synonyms | Psoriasis-associated arthritis mutilans, psoriatic arthritis mutilans |
| C. Adult onset | Adult onset Very high — arthritis mutilans is the most severe form of psoriatic arthritis and occurs almost exclusively in adults. A rare subtype accounting for about 5% or less of psoriatic arthritis. |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
The history of psoriatic arthritis (PsA) began in 1818 when the French physician Jean-Louis Alibert first described joint involvement in patients with psoriasis. However, psoriatic arthritis was established as a distinct clinical entity separate from rheumatoid arthritis in 1964, when Bernard Blumberg and Hollander reported that rheumatoid factor was negative in the joint fluid of psoriasis patients. In 1973, Wright and Moll described five clinical subtypes of psoriatic arthritis (asymmetric small joint arthritis, distal interphalangeal joint arthritis, rheumatoid arthritis-like form, spondylitis form, and arthritis mutilans).
In 2006, the CASPAR (ClASsification criteria for Psoriatic ARthritis) classification criteria for psoriatic arthritis were published, greatly improving diagnostic accuracy. With the introduction of biologics (anti-TNF, anti-IL-17, anti-IL-23), treatment outcomes of PsA improved greatly, and since the 2010s JAK inhibitors (tofacitinib, upadacitinib) and a PDE4 inhibitor (apremilast) have been additionally approved.
Arthritis mutilans is the most severe subtype of psoriatic arthritis and is characterized by osteolysis of the fingers and toes and severe joint destruction. This severe form of joint destruction was already mentioned in Alibert's early description in 1818. The name 'mutilans' derives from the Latin mutilare (to mutilate) and reflects the characteristic that the shortening and deformity of fingers due to osteolysis look as if they had been amputated. The introduction of modern biologics has made it possible to suppress the progression of arthritis mutilans.
The cause of psoriatic arthritis is a combined action of genetic predisposition, environmental factors, and immunological abnormalities. HLA-B27 has a high positivity rate in the spondylitis form (about 50-60%), and HLA-B38, HLA-B39, HLA-Cw6, and others are also associated. In GWAS, IL-12B, IL-23R, TNFAIP3, TRAF3IP2, and others are associated with PsA susceptibility. Skin and joint trauma (the joint analogue of the Koebner phenomenon), streptococcal infection, smoking, and obesity are triggering factors. The IL-23/Th17 axis, TNF-α, and IL-17A/F are the main inflammatory cytokines.
In arthritis mutilans, severe imbalance of the RANKL/RANK/OPG system causes excessive osteoclast activation, leading to extensive osteolysis of the phalanges. IL-17A and TNF-α strongly stimulate RANKL expression, while OPG expression, which inhibits it, is decreased.
The strongest genetic association in psoriatic arthritis is in the HLA region. HLA-Cw6 (PSORS1) is closely associated with psoriatic skin lesions, and HLA-B27 is associated with the spondyloarthritis phenotype (spondylitis, sacroiliitis). In GWAS, IL-12B (p40 subunit), IL-23R (R381Q variant), TRAF3IP2 (ACT1), TNFAIP3 (A20), RUNX3, TYK2, and others have been identified as psoriatic arthritis susceptibility genes. The IL-23R variant provides a biological basis explaining the high efficacy of anti-IL-23 biologics.
Psoriatic arthritis occurs in about 20-30% of patients with psoriasis. The overall prevalence is about 0.1-0.25% of the general population and is estimated at about 0.1% in Korea. Arthritis develops on average 10-15 years after the diagnosis of psoriasis, but in some patients arthritis appears before psoriasis. The incidence in men and women is nearly equal. The median age at diagnosis is in the 30s to 50s.
Arthritis mutilans accounts for about 2-5% of psoriatic arthritis and is its rarest and most severe form. It occurs years to decades after the onset of psoriasis, and delayed diagnosis accelerates joint destruction.
The pathophysiology of psoriatic arthritis centers on the IL-23/Th17 axis. Plasmacytoid dendritic cells (pDC) and dendritic cells in the skin produce IL-23, which activates Th17 cells and ILC3, and IL-17A, IL-17F, and IL-22 are secreted. In the joints, secretion of IL-17 and IL-22 by tissue-resident memory T cells (T_RM) promotes synovial inflammation. TNF-α, IL-6, and IL-1β also contribute to joint destruction. Bone erosion progresses through osteoclast activation caused by RANKL overexpression. On the other hand, new bone formation (periosteal new bone formation) is also a feature of PsA, and the dual 'destructive and constructive' presentation, in which joint ankylosis and bone proliferation appear simultaneously, is specific.
In arthritis mutilans, osteoclast differentiation and activation driven by TNF-α, IL-17, M-CSF, and RANKL overwhelm normal bone homeostasis. Osteoclast activation beginning in the bone marrow of the phalanges leads to dissolution of the whole phalanx, and the 'pencil-in-cup' radiographic finding appears.
Progressive shortening and deformity of the fingers and toes is characteristic. Osteolysis gives the skin an appearance of folding or stretching 'like a balloon' (opera glass hand, telescope hand). Severe joint pain, joint swelling, and functional impairment. Psoriatic skin lesions accompany it, and nail psoriasis (nail pitting, onycholysis) is common. Severe decline in activities of daily living (writing, grasping, etc.).
Shortening of the fingers and toes, skin folds around the joints (telescope sign), joint hypermobility (due to loss of bony support). On X-ray, phalangeal osteolysis, pencil-in-cup deformity, and loss of joint space. Decreased bone density. Elevated CRP/ESR, RF negative (usually), HLA-B27 may be positive.
In patients diagnosed with psoriatic arthritis, monitoring the rate of progression of joint damage is important. Bone erosion and osteolysis are tracked with early X-ray (or MRI/CT) and used to decide treatment intensity. Disease activity is assessed regularly with DAPSA (Disease Activity in PSoriatic Arthritis) or CDAI.
CASPAR criteria: psoriasis (current/past history/family history), negative RF, nail psoriasis, dactylitis, and radiographic findings (juxtaarticular new bone formation) are met. On radiographs, osteolysis and pencil-in-cup deformity are specific findings of arthritis mutilans. MRI is useful for detecting early bone erosion. Rheumatoid arthritis, gouty arthritis, reactive arthritis, and others are differentiated.
Arthritis mutilans is the PsA subtype requiring the most aggressive treatment. Early use of biologics is key to suppressing bone destruction. Anti-TNF (etanercept, adalimumab, infliximab, certolizumab, golimumab): proven effect in suppressing progression of bone erosion. Anti-IL-17 (secukinumab, ixekizumab): excellent effect on both skin and joints. Anti-IL-23p19 (guselkumab, risankizumab): joint and bone protective effect. JAK inhibitors (tofacitinib, upadacitinib): rapid symptom improvement. Reconstructive surgery: when joint stability is lost because of advanced osteolysis, arthrodesis or use of an orthosis may be necessary.
Arthritis mutilans has the worst functional prognosis among PsA. Without early diagnosis and aggressive treatment, it leads to severe functional impairment of the hands and feet. Biologics can suppress progression of bone destruction, but osteolysis that has already occurred does not recover. Early diagnosis (monitoring progression of joint destruction after the diagnosis of psoriatic arthritis) is key to determining prognosis.
In psoriasis patients, early detection of joint involvement through early psoriatic arthritis screening (PEST, ToPAS questionnaires) and starting early DMARD treatment once psoriatic arthritis is confirmed is the best way to prevent progression to arthritis mutilans. A diagnostic delay of 6 months or more markedly increases radiographic damage, so prompt referral to rheumatology is important. Early use of biologics is key to suppressing bone destruction.